Joshua Fitch, Senior Editor

Maegan Ashworth Dirac, MD, PhD, explains how COVID-19 infection risk and low vaccine uptake among pregnant women contributed to a rise in indirect maternal deaths worldwide.

A qualitative sub-study of the COMPASS+ Trial published in Pregnancy found that the Collaborative Care Model is well suited to obstetric settings but requires context-specific adaptation to overcome multilevel barriers.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

89.6% of women tested with Xpert Xpress MVP received appropriate treatment within 24 hours vs 51.9% with usual care.

Daré Bioscience has launched Flora Sync LF5, a non-prescription vaginal probiotic capsule containing Limosilactobacillus fermentum LF5.

A cross-sectional study published in Menopause found that while overall symptom burden was higher in women with average-age menopause, psychological and urogenital symptom scores did not differ significantly.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A study published in Frontiers in Public Health and led by Mount Sinai researchers found that postmenopausal women in lower-income neighborhoods experienced up to 3.8 times greater bone mineral density loss from air pollution exposure than women in wealthier areas, based on data from 9041 participants in the Women's Health Initiative.

A recap of the top-performing, most-viewed Contemporary OB/GYN stories from June 2026, including new SMFM guidance on acetaminophen in pregnancy, ACOG's break from federal vaccine recommendations, and our coverage of SLEEP 2026 in Baltimore.

A recap of the top FDA news stories covered by Contemporary OB/GYN in Q2 2026, spanning cervical cancer screening, menopause therapeutics, and antibiotic treatment for urinary tract infections.

A single-center retrospective cohort study published in Pregnancy found that antibiotic administration after previable PPROM was associated with a 14.7-day increase in latency, along with higher rates of delivery beyond 22 0/7 weeks, lower intrauterine fetal demise, and improved neonatal survival to discharge.

Stephanie Faubion, MD, and Fiona Baker, PhD, discuss how elinzanetant can play a role in sleep disturbances because of VMS, emerging data on the subject, and how to determine the right candidate for the NK1-3 dual-receptor antagonist.

Fiona C. Baker, PhD, explains how menopausal sleep disturbance differs from other forms of sleep disruption, citing the role of vasomotor symptoms, hormone changes, and an increased postmenopausal risk of sleep apnea in driving nighttime awakenings.

Originally approved in February 2020, levonorgestrel and ethinyl estradiol has now received FDA approval for an updated labeled strength expected to appear on the market in the fall of 2026.

In part 2 of our discussion with Fiona Baker, PhD, she details how to interpret data from the NIRVANA study, which revealed reductions in wakefulness after sleep onset in the elinzanetant group vs placebo.

Backed by phase 3 data showing an overall success rate of 58.5% versus 60.2% for IV imipenem-cilastatin, tebipenem HBr has been approved by the FDA as the first oral carbapenem antibiotic for the treatment of complicated urinary tract infections in the US.

A post hoc analysis of the phase 2 NIRVANA trial presented at SLEEP 2026 found that elinzanetant reduced WASO versus placebo across in-lab PSG, home-based Sleepiz One+ monitoring, and patient-reported Sleep Diary.

For the first time, ACOG has released its own version of vaccine recommendations, ones that differ from CDC recommendations.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Aiming to address high maternal mortality rates and close the drug development gap for the 90% of pregnant patients using medications, SMFM's ongoing campaign highlights the vital role of perinatologists in managing high-risk pregnancies.

A cross-sectional analysis of 2024 national survey data published in JAMA Women's Health estimates that 17.9 million US women aged 45 to 64 are overdue for at least 1 recommended cancer screening.

An updated consensus statement from the Society for Maternal-Fetal Medicine confirms that acetaminophen remains the safest first-line treatment for pain and fever during pregnancy.

The FDA has approved Wockhardt’s cefepime and zidebactam, a novel intravenous antibiotic that targets multiple penicillin-binding proteins to treat adults with complicated urinary tract infections.

Nitrofurantoin achieved the highest clinical resolution rates among common UTI antibiotics.

These are the top 5 headlines you might have missed from May 2026.

The Policy Center for Maternal Mental Health's 2026 report cards show a slight national grade improvement to a "C," though a new parental support domain returned an "F" across the United States.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

States with abortion restrictions saw increased expectant management and reliance on less effective treatment regimens for spontaneous abortion.

Cervical cancer screening increased by 2.2 percentage points after program implementation, though 12.6% of eligible individuals received testing kits.

A secondary analysis found that reduced time in target glucose range during labor was associated with increased adverse neonatal outcomes in gestational diabetes.